Prevention of ovarian damage during chemotherapy by
gonadoliberine analogues administration

a 2007

Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration

ŠMARDOVÁ, Lenka, Martin HUSER, Zdeněk KRÁL and Igor CRHA

Basic information

Original name

Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration

Name in Czech

Prevence poškození ovariálních funkcí chemoterapií pomocí analog gonadoliberinu.

Authors

ŠMARDOVÁ, Lenka (203 Czech Republic, guarantor), Martin HUSER (203 Czech Republic), Zdeněk KRÁL (203 Czech Republic) and Igor CRHA (203 Czech Republic)

Edition

Haematologica/The Hematology Journal, 2007

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30214 Obstetrics and gynaecology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.516

RIV identification code

RIV/00216224:14110/07:00019137

Organization unit

Faculty of Medicine

ISSN

UT WoS

000250470800127

Keywords in English

Hodgkins lymphoma; gonadoliberine analogues; premature ovarian failure

Abstract

ORIG CZ

V originále

Background: The risk of POF onset depends mainly on womens age and foliculogenesis status in ovary, chemotherapy (CT) regimen used and cumulative dose of single cytotoxic agents. Aims: Aim of this prospective case-control study is evaluation of gonadoliberine analogues (GnRHa) administration to patients with Hodgkins lymphoma (HL) during chemotherapy and prevention of ovarian damage depending upon CT dose and regimen. Methods: Study group consists of 72 patients in fertile age with HL by curative CT together with GnRHa administration according standardized protocol. Group A received ABVD, group B baseline BEACOPP and ABVD in combination, group C dose escalated BEACOPP regimen. Results: In study group with GnRHa administration during CT there was statistical significantly less cases with POF (38.2 %) in 6 month after end of CT than in control group (73.4 %). After 12 month POF was detected in 48.8 % of cases versus 69.3 % in control group. Summary: Study proved significant reduction of ovarian failure risk in women with HL treated with less aggressive CT regimens.

In Czech

Prevence poškození ovariálních funkcí chemoterapií pomocí analog gonadoliberinu.

Links

NR8469, research and development project

Name: Možnosti ochrany reprodukčních funkcí u žen podstupujících chemoterapii pro hematologickou malignitu

Citovat

ŠMARDOVÁ, Lenka, Martin HUSER, Zdeněk KRÁL and Igor CRHA. Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration (Prevention Of Ovarian Damage During Chemotherapy By Gonadoliberine Analogues Administration). In Haematologica/The Hematology Journal. 2007. ISSN 0390-6078.

@proceedings{747094,
   author = {Šmardová, Lenka and Huser, Martin and Král, Zdeněk and Crha, Igor},
   booktitle = {Haematologica/The Hematology Journal},
   keywords = {Hodgkins lymphoma; gonadoliberine analogues; premature ovarian failure},
   language = {eng},
   title = {Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration},
   year = {2007}
}

TY  - CONF
ID  - 747094
AU  - Šmardová, Lenka - Huser, Martin - Král, Zdeněk - Crha, Igor
PY  - 2007
TI  - Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration
KW  - Hodgkins lymphoma
KW  - gonadoliberine analogues
KW  - premature ovarian failure
N2  - Background: The risk of POF onset depends mainly on womens age and foliculogenesis status in ovary, chemotherapy (CT) regimen used and cumulative dose of single cytotoxic agents. Aims: Aim of this prospective case-control study is evaluation of gonadoliberine analogues (GnRHa) administration to patients with Hodgkins lymphoma (HL) during chemotherapy and prevention of ovarian damage depending upon CT dose and regimen. Methods: Study group consists of 72 patients in fertile age with HL by curative CT together with GnRHa administration according standardized protocol. Group A received ABVD, group B baseline BEACOPP and ABVD in combination, group C dose escalated BEACOPP regimen. Results: In study group with GnRHa administration during CT there was statistical significantly less cases with POF (38.2 %) in 6 month after end of CT than in control group (73.4 %). After 12 month POF was detected in 48.8 % of cases versus 69.3 % in control group. Summary: Study proved significant reduction of ovarian failure risk in women with HL treated with less aggressive CT regimens.
ER  -

ŠMARDOVÁ, Lenka, Martin HUSER, Zdeněk KRÁL and Igor CRHA. Prevention of ovarian damage during chemotherapy by gonadoliberine analogues administration (Prevention Of Ovarian Damage During Chemotherapy By Gonadoliberine Analogues Administration). In \textit{Haematologica/The Hematology Journal}. 2007. ISSN~0390-6078.

Detailed Information on Publication Record